SG11202103415WA - Compositions and methods for treating and preventing amyotrophic lateral sclerosis - Google Patents
Compositions and methods for treating and preventing amyotrophic lateral sclerosisInfo
- Publication number
- SG11202103415WA SG11202103415WA SG11202103415WA SG11202103415WA SG11202103415WA SG 11202103415W A SG11202103415W A SG 11202103415WA SG 11202103415W A SG11202103415W A SG 11202103415WA SG 11202103415W A SG11202103415W A SG 11202103415WA SG 11202103415W A SG11202103415W A SG 11202103415WA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- treating
- methods
- lateral sclerosis
- amyotrophic lateral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779916P | 2018-12-14 | 2018-12-14 | |
| US201962807603P | 2019-02-19 | 2019-02-19 | |
| US201962840879P | 2019-04-30 | 2019-04-30 | |
| PCT/US2019/065936 WO2020123783A1 (en) | 2018-12-14 | 2019-12-12 | Compositions and methods for treating and preventing amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103415WA true SG11202103415WA (en) | 2021-06-29 |
Family
ID=69160351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103415WA SG11202103415WA (en) | 2018-12-14 | 2019-12-12 | Compositions and methods for treating and preventing amyotrophic lateral sclerosis |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220073930A1 (zh) |
| EP (1) | EP3894557A1 (zh) |
| JP (1) | JP2022513597A (zh) |
| KR (1) | KR20210131992A (zh) |
| CN (1) | CN113330116A (zh) |
| AU (1) | AU2019396522A1 (zh) |
| BR (1) | BR112021011334A2 (zh) |
| CA (1) | CA3115549A1 (zh) |
| CL (1) | CL2021001136A1 (zh) |
| CO (1) | CO2021008187A2 (zh) |
| CR (1) | CR20210384A (zh) |
| IL (1) | IL283833A (zh) |
| JO (1) | JOP20210143A1 (zh) |
| MX (1) | MX2021005086A (zh) |
| PH (1) | PH12021551365A1 (zh) |
| SG (1) | SG11202103415WA (zh) |
| TW (1) | TW202035694A (zh) |
| UY (1) | UY38506A (zh) |
| WO (1) | WO2020123783A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019147960A1 (en) | 2018-01-25 | 2019-08-01 | Biogen Ma Inc. | Methods of treating spinal muscular atrophy |
| CA3214585A1 (en) * | 2021-03-31 | 2022-10-06 | Biogen Ma Inc. | Treatment of amyotrophic lateral sclerosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| WO2013134403A1 (en) * | 2012-03-06 | 2013-09-12 | The Washington University | Method of treating neurodegenerative diseases with microrna regulators |
| IL247600B (en) * | 2014-03-19 | 2022-06-01 | Ionis Pharmaceuticals Inc | Preparations for the modulation of ataxin 2 expression |
| HRP20220798T1 (hr) * | 2014-04-01 | 2022-10-14 | Biogen Ma Inc. | Pripravci za modulaciju ekspresije sod-1 |
| EP3618839A4 (en) * | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND TREATMENT METHODS FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| EP3631470A4 (en) * | 2017-05-26 | 2021-03-24 | University of Miami | DETERMINATION OF THE ONSET OF AMYOTROPHIC LATERAL SCLEROSIS |
-
2019
- 2019-12-06 TW TW108144617A patent/TW202035694A/zh unknown
- 2019-12-11 UY UY0001038506A patent/UY38506A/es unknown
- 2019-12-12 CR CR20210384A patent/CR20210384A/es unknown
- 2019-12-12 BR BR112021011334-7A patent/BR112021011334A2/pt unknown
- 2019-12-12 US US17/291,199 patent/US20220073930A1/en active Pending
- 2019-12-12 SG SG11202103415WA patent/SG11202103415WA/en unknown
- 2019-12-12 KR KR1020217020529A patent/KR20210131992A/ko unknown
- 2019-12-12 MX MX2021005086A patent/MX2021005086A/es unknown
- 2019-12-12 CA CA3115549A patent/CA3115549A1/en active Pending
- 2019-12-12 JO JOP/2021/0143A patent/JOP20210143A1/ar unknown
- 2019-12-12 JP JP2021525191A patent/JP2022513597A/ja active Pending
- 2019-12-12 AU AU2019396522A patent/AU2019396522A1/en active Pending
- 2019-12-12 WO PCT/US2019/065936 patent/WO2020123783A1/en unknown
- 2019-12-12 EP EP19836331.9A patent/EP3894557A1/en active Pending
- 2019-12-12 CN CN201980080996.2A patent/CN113330116A/zh active Pending
-
2021
- 2021-04-29 CL CL2021001136A patent/CL2021001136A1/es unknown
- 2021-06-09 IL IL283833A patent/IL283833A/en unknown
- 2021-06-09 PH PH12021551365A patent/PH12021551365A1/en unknown
- 2021-06-23 CO CONC2021/0008187A patent/CO2021008187A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202035694A (zh) | 2020-10-01 |
| IL283833A (en) | 2021-07-29 |
| US20220073930A1 (en) | 2022-03-10 |
| JOP20210143A1 (ar) | 2023-01-30 |
| CO2021008187A2 (es) | 2021-09-09 |
| PH12021551365A1 (en) | 2021-11-22 |
| WO2020123783A1 (en) | 2020-06-18 |
| CL2021001136A1 (es) | 2022-01-14 |
| CA3115549A1 (en) | 2020-06-18 |
| CR20210384A (es) | 2021-12-20 |
| EP3894557A1 (en) | 2021-10-20 |
| JP2022513597A (ja) | 2022-02-09 |
| UY38506A (es) | 2020-06-30 |
| CN113330116A (zh) | 2021-08-31 |
| MX2021005086A (es) | 2021-08-16 |
| BR112021011334A2 (pt) | 2021-09-08 |
| AU2019396522A1 (en) | 2021-05-06 |
| KR20210131992A (ko) | 2021-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006627B (en) | Methods and compositions for treating cancer | |
| EP3618839A4 (en) | COMPOSITIONS AND TREATMENT METHODS FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) | |
| EP3119797A4 (en) | Raav-based compositions and methods for treating amyotrophic lateral sclerosis | |
| SG11201705767PA (en) | Agent for preventing and/or treating amyotrophic lateral sclerosis | |
| PL3668509T3 (pl) | Sposób leczenia stwardnienia zanikowego bocznego pridopidiną | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| IL285886A (en) | Preparations and methods for the treatment of laminopathy | |
| SG11202012435UA (en) | Compositions and methods for treating cancer | |
| IL288024A (en) | Methods and preparations for the prevention of type 1 diabetes | |
| SG11202112515RA (en) | Methods and compositions for treating liver disorders | |
| IL281394A (en) | Method and preparation for the prevention and treatment of arteriosclerosis and related diseases | |
| IL283833A (en) | Preparations and methods for the treatment and prevention of lateral column sclerosis in the spine | |
| IL285796A (en) | Methods and preparations for the treatment of cancer | |
| EP3801620A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PANCREATITIS | |
| GB202214988D0 (en) | Compositions and methods for preventing or treating nephrolithiasis | |
| IL277332A (en) | Preparations and methods for treating severe constipation | |
| IL277463A (en) | Vehicles and methods for treating itch | |
| PL3810128T3 (pl) | Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek | |
| IL260331A (en) | Composition and method for treating amyotrophic lateral sclerosis | |
| EP3595640A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| IL282948A (en) | Preparations and methods for the treatment of cancer | |
| IL261360A (en) | Compound and method for treating amyotrophic lateral sclerosis | |
| IL279907A (en) | Preparations and methods for treating stroke | |
| IL280965A (en) | Methods of treating or preventing amyotrophic lateral sclerosis | |
| IL261908A (en) | Methods of treating amyotrophic lateral sclerosis |